On Tuesday, Ascendiant Capital revised its value goal for NASDAQ:PSTV, Plus Therapeutics (NASDAQ:) Inc., to $20.00 from the earlier $21.00, whereas retaining a Purchase ranking on the inventory. The adjustment follows the corporate’s reported Q2 2024 monetary outcomes on August 14, which confirmed revenues and earnings per share (EPS) under analyst and consensus expectations.
Plus Therapeutics disclosed a Q2 income of $1.3 million, falling wanting the anticipated $1.6 to $1.7 million vary. The corporate additionally reported an EPS of $(0.71), with a web lack of $7.6 million, which was not in keeping with the estimated $(0.37) and consensus of $(0.53). Notably, Plus Therapeutics had not supplied any monetary steering for Q2.
The absence of economic steering for the 12 months 2024 from the administration was famous. Nonetheless, Ascendiant Capital means that the present quarterly money burn charge of roughly $3 million may very well be a believable near-term expectation.
The agency has consequently revised its 2024 income estimates for Plus Therapeutics, decreasing the forecast from $7 million to $5 million, and adjusted the EPS estimate to $(2.00) from the earlier $(1.69).
The modifications within the monetary outlook for Plus Therapeutics replicate the most recent earnings miss and the shortage of steering from the corporate’s administration.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
